Case Study: Xentria advances sarcoidosis drug development with Certara's PK modeling and medical writing expertise

Leveraging Pharmacokinetic Modeling & Scientific Communications Expertise Advances Sarcoidosis Drug Program

Xentria, a pioneering biopharmaceutical company, needed to identify optimal dosing regimens for its novel pulmonary sarcoidosis treatment, XTMAB-16, and lacked in-house expertise to publish its research findings. They partnered with Certara to address these challenges using their pharmacometric modeling and medical communications services.

Certara scientists utilized Phoenix NLME software to develop a population pharmacokinetic model, which identified the optimal dosage levels through Monte-Carlo simulations. This provided invaluable guidance for Xentria's clinical development program. Furthermore, Certara's medical writing team transformed the study data into a manuscript that was successfully published in Frontiers in Pharmacology. Certara's comprehensive support empowered Xentria to advance its research and share its findings with the scientific community.

Xentria